Cargando…
Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic systemic inflammatory disease associated with a high prevalence of cardiovascular disease (CVD). Hydroxychloroquine (HCQ) is commonly used to control disease activity in patients with SLE. We evaluated its potential additional therapeutic effect for re...
Autores principales: | Yang, Deng-Ho, Leong, Pui-Ying, Sia, Sung-Kien, Wang, Yu-Hsun, Wei, James Cheng-Chung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616930/ https://www.ncbi.nlm.nih.gov/pubmed/31195632 http://dx.doi.org/10.3390/jcm8060796 |
Ejemplares similares
-
Association between endometriosis and risk of systemic lupus erythematosus
por: Fan, Yu-Hsi, et al.
Publicado: (2021) -
Hydroxychloroquine ototoxicity in a patient with systemic lupus
erythematosus
por: Fernandes, Mariana Rita de Novaes, et al.
Publicado: (2018) -
Hydroxychloroquine-induced retinal toxicity in systemic lupus erythematosus
por: Piggott, Kisha D, et al.
Publicado: (2018) -
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
por: Dima, Alina, et al.
Publicado: (2022) -
Systemic Lupus Erythematosus: Perinatal Outcomes in Patients Treated With and Without Hydroxychloroquine
por: Baalbaki, Sima, et al.
Publicado: (2020)